MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering

The acquisition gives MDxHealth access to a validated, non-invasive liquid biopsy test for prostate cancer in the US and EU Urine based test shown to be clinically superior to PCA3 prostate cancer test $8.8 million total acquisition cost, including $5.1 million in...